LAIYANG, China, April 23 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (BULLETIN BOARD: GNPH) (the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it has changed its name to "Jiangbo Pharmaceuticals, Inc." ("Jiangbo").
The Company received confirmation from the Department of State of the State of Florida that the Certificate of Amendment to the Company's Amended and Restated Articles of Incorporation to effect a change of its name was filed. The Board of Directors of the Company as well as the holders of a majority of the outstanding shares of the Company's voting stock approved the name change by written consent. The Company will soon receive a new CUSIP number for its common stock, after which a new ticker symbol for the Company's shares will be assigned by the OTCBB. The Company will announce its new ticker symbol and CUSIP number as soon as it receives them.
The Company's wholly owned operating subsidiary Laiyang Jiangbo Pharmaceutical Co., Ltd., a PRC company, markets the Company's products throughout China under the brand name "Jiangbo." Part of the Company's branding strategy includes using similar packaging for its products and creating a product line of drugs which are widely known by Jiangbo's brand name and logo.
"We support Jiangbo with the idea that 'We aim high, We aim wide.' It is part of our corporate culture to provide our customers with products that will help them lead happy and healthy lives. We always strive to produce the best possible quality products and ensure our reputation while we continue to grow our Company's revenues, profits and value," said Mr. Wubo Cao, Chief Executive Officer of Jiangbo.
"We changed our corporate name to Jiangbo to align the name of our public company with the name of our products. With this change, we hope that our customers, partners and shareholders will view our products as synonymous with our Company. We want people to think of only 'Jiangbo' as we continue to improve our Company and expand our product line," concluded Mr. Cao.
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com/
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact: Jiangbo Pharmaceuticals, Inc. Ms. Elsa Sung, CFO Phone: +1-954-727-8435 Email: elsasung@jiangbo.com Web: http://www.jiangbopharma.com/ CCG Investor Relations, Inc. Mr. Crocker Coulson, President Phone: +1-646-213-1915 Email: crocker.coulson@ccgir.com Web: http://www.ccgirasia.com/
Genesis Pharmaceuticals Enterprises, Inc.
CONTACT: Jiangbo Pharmaceuticals, Inc., Ms. Elsa Sung, CFO, +1-954-727-
8435, elsasung@jiangbo.com or CCG Investor Relations, Inc., Mr. Crocker
Coulson, President, +1-646-213-1915, crocker.coulson@ccgir.com for Jiangbo
Pharmaceuticals, Inc.
Web site: http://www.jiangbopharma.com/
